NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free TCRX Stock Alerts $8.98 +0.08 (+0.90%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$8.74▼$9.0150-Day Range$6.56▼$8.9952-Week Range$1.93▼$9.36Volume177,730 shsAverage Volume179,840 shsMarket Capitalization$474.68 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get TScan Therapeutics alerts: Email Address TScan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.6% Upside$12.00 Price TargetShort InterestHealthy1.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 38 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.25) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector507th out of 920 stocksBiological Products, Except Diagnostic Industry75th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about TScan Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.03% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently decreased by 5.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 1.1 News and Social Media Coverage News SentimentTScan Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.76% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.25) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TScan Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."And these will be the biggest winners About TScan Therapeutics Stock (NASDAQ:TCRX)TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More TCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRX Stock News HeadlinesMay 19 at 4:40 AM | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Analysts at BTIG ResearchMay 17 at 4:36 AM | americanbankingnews.comLifesci Capital Research Analysts Decrease Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)May 16 at 5:28 PM | msn.comBTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy RecommendationMay 16 at 6:46 AM | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)May 16 at 5:08 AM | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by HC WainwrightMay 16 at 1:24 AM | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Forecasted to Post Q2 2024 Earnings of ($0.25) Per ShareMay 16 at 1:24 AM | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Forecasted to Earn Q2 2024 Earnings of ($0.23) Per ShareMay 15, 2024 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Given "Outperform" Rating at WedbushMay 15, 2024 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Needham & Company LLCMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: TScan Therapeutics’ Innovative TCR-T Therapy and Strategic Milestones Promising for 2024May 14, 2024 | finance.yahoo.comTScan Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)May 13, 2024 | markets.businessinsider.comKey Takeaways From TScan Therapeutics Analyst RatingsMay 13, 2024 | investorplace.comTCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | globenewswire.comTScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Amid Innovative Tumor Treatment and Promising Clinical TrialsMay 9, 2024 | globenewswire.comTScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid TumorsApril 24, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingApril 24, 2024 | globenewswire.comTScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesApril 23, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On TScan TherapeuticsApril 22, 2024 | globenewswire.comTScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 22, 2024 | seekingalpha.comSimplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And BeyondApril 19, 2024 | globenewswire.comTScan Therapeutics Announces Closing of Upsized Public OfferingApril 18, 2024 | investing.comTScan launches $125 million public stock offeringApril 17, 2024 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesSee More Headlines Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/19/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees154Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+33.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,220,000.00 Net Margins-653.50% Pretax Margin-653.50% Return on Equity-61.13% Return on Assets-34.53% Debt Debt-to-Equity Ratio0.19 Current Ratio5.23 Quick Ratio6.51 Sales & Book Value Annual Sales$21.05 million Price / Sales22.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book3.85Miscellaneous Outstanding Shares52,860,000Free Float46,560,000Market Cap$474.68 million OptionableNot Optionable Beta0.91 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Gavin MacBeath Ph.D. (Age 54)CEO & Director Comp: $650.17kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Jason A. Amello (Age 56)Chief Financial Officer Mr. Leiden Dworak M.B.A.Principal Accounting Officer & TreasurerDr. Justin McCue Ph.D.Chief Technology OfficerMs. Ann HargravesSenior Vice President of Human ResourcesDr. Shrikanta Chattopadhyay M.D.Senior VP & Head of Translational MedicineMore ExecutivesKey CompetitorsOcugenNASDAQ:OCGNLexeo TherapeuticsNASDAQ:LXEOC4 TherapeuticsNASDAQ:CCCCReplimune GroupNASDAQ:REPLVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 20,000 shares on 5/10/2024Ownership: 3.776%Tocqueville Asset Management L.P.Bought 212,200 shares on 5/10/2024Ownership: 0.443%Cannon Global Investment Management LLCBought 17,500 shares on 4/17/2024Ownership: 0.037%Timothy J BarberichBought 28,830 shares on 12/18/2023Total: $140,978.70 ($4.89/share)Barbara KlenckeBought 5,000 shares on 12/14/2023Total: $25,400.00 ($5.08/share)View All Insider TransactionsView All Institutional Transactions TCRX Stock Analysis - Frequently Asked Questions Should I buy or sell TScan Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks. What is TScan Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 12-month price targets for TScan Therapeutics' stock. Their TCRX share price targets range from $10.00 to $15.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 33.6% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts. How have TCRX shares performed in 2024? TScan Therapeutics' stock was trading at $5.83 on January 1st, 2024. Since then, TCRX stock has increased by 54.0% and is now trading at $8.98. View the best growth stocks for 2024 here. When is TScan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TCRX earnings forecast. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The business earned $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 61.13% and a negative net margin of 653.50%. What ETF holds TScan Therapeutics' stock? Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 9.44% of its portfolio. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? TScan Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.78%), Tocqueville Asset Management L.P. (0.44%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Barbara Klencke, Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.